Unmasking the Mechanism behind Miltefosine: Revealing the Disruption of Intracellular Ca2+ Homeostasis as a Rational Therapeutic Target in Leishmaniasis and Chagas Disease

Biomolecules. 2024 Mar 27;14(4):406. doi: 10.3390/biom14040406.

Abstract

Originally developed as a chemotherapeutic agent, miltefosine (hexadecylphosphocholine) is an inhibitor of phosphatidylcholine synthesis with proven antiparasitic effects. It is the only oral drug approved for the treatment of Leishmaniasis and American Trypanosomiasis (Chagas disease). Although its precise mechanisms are not yet fully understood, miltefosine exhibits broad-spectrum anti-parasitic effects primarily by disrupting the intracellular Ca2+ homeostasis of the parasites while sparing the human hosts. In addition to its inhibitory effects on phosphatidylcholine synthesis and cytochrome c oxidase, miltefosine has been found to affect the unique giant mitochondria and the acidocalcisomes of parasites. Both of these crucial organelles are involved in Ca2+ regulation. Furthermore, miltefosine has the ability to activate a specific parasite Ca2+ channel that responds to sphingosine, which is different to its L-type VGCC human ortholog. Here, we aimed to provide an overview of recent advancements of the anti-parasitic mechanisms of miltefosine. We also explored its multiple molecular targets and investigated how its pleiotropic effects translate into a rational therapeutic approach for patients afflicted by Leishmaniasis and American Trypanosomiasis. Notably, miltefosine's therapeutic effect extends beyond its impact on the parasite to also positively affect the host's immune system. These findings enhance our understanding on its multi-targeted mechanism of action. Overall, this review sheds light on the intricate molecular actions of miltefosine, highlighting its potential as a promising therapeutic option against these debilitating parasitic diseases.

Keywords: Ca2+ channel; Ca2+ regulation; Ca2+ signaling; acidocalcisome; miltefosine; mitochondria; sphingosine.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiprotozoal Agents / pharmacology
  • Antiprotozoal Agents / therapeutic use
  • Calcium* / metabolism
  • Chagas Disease* / drug therapy
  • Chagas Disease* / metabolism
  • Chagas Disease* / parasitology
  • Homeostasis* / drug effects
  • Humans
  • Leishmania / drug effects
  • Leishmania / metabolism
  • Leishmaniasis* / drug therapy
  • Leishmaniasis* / metabolism
  • Leishmaniasis* / parasitology
  • Mitochondria / drug effects
  • Mitochondria / metabolism
  • Phosphorylcholine* / analogs & derivatives*
  • Phosphorylcholine* / pharmacology
  • Phosphorylcholine* / therapeutic use
  • Trypanosoma cruzi / drug effects
  • Trypanosoma cruzi / metabolism

Substances

  • miltefosine
  • Phosphorylcholine
  • Calcium
  • Antiprotozoal Agents